Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

Michael O'Riordan

January 25, 2021

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Features

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Shelley Wood

April 21, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

Advertisement

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

FDA approves Repatha to treat certain patients with high cholesterol

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content